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Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory disease that
produces synovial proliferation and joint erosions. The
pathologic lesions of RA are driven through the production of
inflammatory mediators in the synovium mediated, in part, by the
transcription factor NF-κB. We have identified a non-steroidal
estrogen receptor ligand, WAY-169916, that selectively inhibits
NF-κB transcriptional activity but is devoid of conventional
estrogenic activity. The activity of WAY-169916 was monitored
in two models of arthritis, the HLA-B27 transgenic rat and the
Lewis rat adjuvant-induced model, after daily oral administration.
In both models, a near complete reversal in hindpaw scores was
observed as well as marked improvements in the histological
scores. In the Lewis rat adjuvant model, WAY-169916 markedly
suppresses the adjuvant induction of three serum acute phase
proteins: haptoglobin, α1-acid glycoprotein (α1-AGP), and C-
reactive protein (CRP). Gene expression experiments also
demonstrate a global suppression of adjuvant-induced gene
expression in the spleen, liver, and popliteal lymph nodes.
Finally, WAY-169916 was effective in suppressing tumor
necrosis factor-α-mediated inflammatory gene expression in
fibroblast-like synoviocytes isolated from patients with RA.
Together, these data suggest the utility of WAY-169916, and
other compounds in its class, in treating RA through global
suppression of inflammation via selective blockade of NF-κB
transcriptional activity.
Introduction
Rheumatoid arthritis (RA) is a chronic, debilitating condi-
tion affecting 0.5 to 1% of the world's population. The
major goals of treatment of RA are to reduce pain and dis-
comfort, to prevent deformities and loss of joint function,
and to maintain a productive and active lifestyle. RA is char-
acterized by chronic joint inflammation mediated by inflam-
matory cell infiltration into synovial tissues as well as joint
destruction through the overexpression of matrix metallo-
proteinase (MMP) in articular synoviocytes and chondro-
cytes. The pathologic lesions of RA are driven, in part, by
the production of inflammatory mediators in synoviocytes
and macrophages, probably involving the transcription fac-
tor NF-κB. Because NF-κB is localized in the nuclei of syn-
ovial cells in patients with RA [1,2] and the inducers and
targets of NF-κB almost perfectly match the list of pivotal
mediators increased in RA [3], an important role for acti-
vated NF-κB in human RA is likely.R427
α1-AGP = α1-acid glycoprotein; ANOVA = analysis of variance; CFA = complete Freund's adjuvant; ConA = concanavalin A; CRP = C-reactive 
protein; ER = estrogen receptor; FLS = fibroblast-like synoviocytes; ICAM-1 = intercellular cell-adhesion molecule-1; IκB = inhibitory protein-κB; IL 
= interleukin; LBP = LBS binding protein; MMP = matrix metalloproteinase; NF-κB = nuclear factor-κB; PDTC = pyrrolidine dithiocarbamate; RA = 
rheumatoid arthritis; RT–PCR = reverse transcriptase polymerase chain reaction; TNF-α = tumor necrosis factor-α.
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R428NF-κB is a dimeric transcription factor composed of
homodimeric and heterodimeric complexes of the Rel fam-
ily of proteins, p65 (Rel A), p50/105, c-Rel, p52/100, and
Rel B. Binding of cytoplasmic inhibitory protein-κB (IκB) to
NF-κB masks the NF-κB nuclear localization signal and
sequesters NF-κB in a non-activated form in the cytoplasm.
Cell activation by a variety of extracellular signals such as
oxidative stress, cytokines, and lipopolysaccharide induces
a cascade of events that leads to the degradation of IκB;
activated NF-κB then translocates to the nucleus, where it
binds to DNA elements in the promoters of several proin-
flammatory gene families [4].
Activation of NF-κB has been observed in synovial cells
from patients with RA [5] and results in the induction of
proinflammatory genes such as tumor necrosis factor-α
(TNF-α), IL-1β, IL-6, MMP-1, and MMP-3 in ex vivo synovial
membrane cultures [6]. Moreover, NF-κB activation might
also be a pivotal factor protecting cells from apoptosis,
thus contributing to synovial hyperplasia (reviewed in [7]).
Inactivation of NF-κB in transgenic mice expressing a
'super-repressor' IκBα or in rel- /- and nfkb1- /- knockout
mice rendered the animals refractory to development of col-
lagen-induced arthritis [8,9]. In another study performed in
the rat adjuvant-induced arthritis model, intra-articular injec-
tion of an adenoviral construct encoding a dominant-nega-
tive from of IκB kinase-2 significantly ameliorated the
severity of the adjuvant arthritis and was correlated with a
decrease in NF-κB DNA binding in the nucleus of synovial
cells [10]. Because NF-κB is involved in normal immune
and homeostatic processes, its prolonged inhibition might
be harmful. Therefore, more indirect methods of targeting
NF-κB might provide a safer pharmacological profile.
In tissues that express estrogen receptor (ER), 17β-estra-
diol inhibits NF-κB-driven transcription through multiple
mechanisms that might include direct protein–protein inter-
actions [11,12], inhibition of NF-κB binding to DNA
[13,14], induction of IκB expression [15], or coactivator
sharing [16,17]. Two nuclear estrogen receptors have
been identified (ERα and ERβ). Both receptors are widely
distributed throughout numerous organs [18] and are
present in T cells, monocytes, dendritic cells, synovial mac-
rophages, articular chondrocytes, and proliferating fibrob-
lasts present in the RA joint [19-22]. These two receptors
have a nearly identical DNA-binding domain, both activate
transcription through binding to identical ER response ele-
ments [23,24], and both can antagonize NF-κB transcrip-
tional activity [25,26]. Taken together, these findings
identify RA as a disease amenable to treatment with ER-
selective NF-κB inhibitors.
The selective inflammatory modulator WAY-169916 is a
non-steroidal ER-dependent inhibitor of NF-κB transcrip-
tional activity. Although it inhibits the expression of a range
of inflammatory proteins, including cytokines, chemokines,
and cell adhesion molecules that are expressed after acti-
vation of NF-κB, WAY-169916 lacks estrogenic activity
such as the stimulation of uterine proliferation [27]. Here
we demonstrate that WAY-169916 is efficacious in two
models of arthritis, the HLA-B27 transgenic rat and a Lewis
rat model of adjuvant-induced arthritis. The activity of WAY-
169916 is related to its ability to suppress inflammatory
processes globally, as demonstrated by the decrease in
serum acute-phase protein levels of haptoglobin, α1-acid
glycoprotein (α1-AGP), and C-reactive protein (CRP) as
well as the inhibition of adjuvant-induced gene expression
in the spleen, liver, and popliteal lymph nodes in the rat
adjuvant arthritis model. Moreover, WAY-169916 was also
active in suppressing cytokine and adhesion molecule
expression in fibroblast-like synoviocytes (FLS) isolated
from patients with RA. Taken together, these data suggest
the potential utility of the pathway-selective ER ligand




Male HLA-B27 transgenic rats were obtained from
Taconic; the Lewis rats were purchased from Charles River
Laboratories. The rats were housed in accordance with
standard operating procedures and were provided with
food and water ad libitum. All experiments were approved
and performed in accordance with the Wyeth Animal Care
and Use Committee standards.
HLA-B27 transgenic rat model arthritis
HLA-B27 transgenic rats, 26 to 28 weeks old, experienc-
ing maximal clinical signs of arthritis with a score of 12,
using a scale of 0 to 3 for swelling and for erythema of the
hindpaws (0, normal paw; 1, mild; 2, moderate; 3, severe)
were treated with vehicle (2% Tween 80, 0.5% methylcel-
lulose), prednisolone (0.6 mg/kg), or WAY-169916 (10
mg/kg) given orally once daily for 29 days with four rats per
group. At necropsy, the tarsal joints were removed and pre-
pared for histological examination. After decalcification, his-
tological sections were stained with hematoxylin and eosin
or Safranin O/Fast Green stain. Synovial tissue from tarsal
joints was evaluated on the basis of synovial hyperplasia,
fibroplasia, inflammatory cell infiltration, and pannus forma-
tion [28].
Articular cartilage was evaluated with Mankin's histological
grading system [29]. The scoring system evaluates the
structure of the articular cartilage, ranging from 0 (normal),
1 (surface irregularity), 2 (pannus and surface irregularity),
3 (clefts to transititional zone), 4 (clefts to radial zone), 5
(clefts to the calcified zone), to 6 (complete disorganiza-
tion; cartilage cells, ranging from 0 (normal), 1 (diffuse
hypercellularity), 2 (cloning), to 3 (hypocellularity); Safranin-
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R429O staining to assess proteoglycan content, ranging from 0
(normal), 1 (slight reduction), 2 (modest reduction), 3
(severe reduction), to 4 (no staining); and tidemark integ-
rity, ranging from 0 (intact) to 1 (crossed by blood vessels).
The scores for eachtarsal joint were tabulated and
summed, and amean score was derived for each animal,
ranging from 0 to 14. Statistical analysis was performed
with Abacus Concepts Super ANOVA (Abacus Concepts,
Inc., Berkeley, CA). All parameters of interest were sub-
jected to analysis of variance (ANOVA) with Duncan's new
multiple-range post hoc testing between groups. Data are
expressed throughout as means ± standard deviation (SD),
and differences were deemed significant if P < 0.05.
Rat adjuvant-induced arthritis model
Arthritis was induced in the Lewis rats with complete Fre-
und's adjuvant (CFA) by intradermal injection of 0.1 mg of
heat-killed and dried Mycobacterium tuberculosis in 0.1 ml
of mineral oil, at the base of the tail. Eight days after adju-
vant injection, when the rats were experiencing maximal
clinical signs of arthritis with a score of 12 using the same
hindpaw scoring system described above, treatment
began. Male Lewis rats (n = 6) received orally delivered
vehicle (2.0% Tween 80, 0.5% methylcellulose, 1 ml/kg) or
WAY-169916 (5.0, 0.3, or 0.1 mg/kg) once daily for 10 to
14 days, with six rats in each group. The clinical signs of
arthritis were monitored daily. At the end of the experiment,
terminal blood samples were obtained and the tarsal joints
were prepared for histological examination and graded as
described above. Statistical analysis was performed with
Abacus Concepts Super ANOVA. All parameters of inter-
est were subjected to ANOVA with Duncan's new multiple-
range post hoc testing between groups. The serum sam-
ples were used to determine the levels of haptoglobin, α1-
AGP, and CRP by radial immunodiffusion test kits in
accordance with manufacturer's protocol (Life Diagnostics
Inc.). The data were analyzed by one-way ANOVA and are
expressed as means ± SD, and differences were deemed
significant if P < 0.05.
Gene expression profiling experiments were conducted
with RNA isolated from the spleen, liver, and popliteal
lymph nodes, using Affymetrix REA230A oligonucleotide
arrays (Affymetrix) in accordance with the manufacturer's
recommendations. The arrays were washed and stained
with Streptavidin R–phycoerythrin (Molecular Probes) with
the use of the GeneChip® Fluidics Station 400, and
scanned with a Hewlett Packard GeneArray Scanner in
accordance with the manufacturer's instructions. Fluores-
cent data were collected and converted to gene-specific
difference averages with MicroArray Suite 4.0 software. A
representative set of genes regulated by WAY-169916
was confirmed by real-time RT–PCR analysis. All mRNA
levels were normalized for glyceraldehyde-3-phosphate
dehydrogenase expression. The data were analyzed by
one-way ANOVA and expressed as means ± SD, and dif-
ferences were deemed significant if P < 0.05.
NF-κB DNA binding experiments
Mouse splenocytes were prepared by creating single-cell
suspensions, with the subsequent removal of red blood
cells with Tris-NH4Cl solution. After lysis of red blood cells,
the cells were cultured in 24-well plates at a concentration
of 106 cells/ml in RPMI-10 (RPMI medium containing 10%
heat-inactivated fetal bovine serum, 100 U/ml penicillin,
100 µg/ml streptomycin, 2 mM glutamine, and 50 µM 2-
mercaptoethanol; Invitrogen, Carlsbad, CA). The cells were
stimulated with concanavalin A (ConA) and co-treated with
either WAY-169916 (1 µM) or pyrrolidine dithiocarbamate
(PDTC; 100 µM) for 18 hours. Nuclear extract preparation
and NF-κB DNA binding experiments were conducted with
kits purchased from Active Motif.
Experiments with FLS
Human FLS isolated from patients with RA were purchased
from Cell Applications, Inc. The cells were cultured in syn-
oviocyte growth medium (Cell Applications, Inc.) and
seeded at 3 × 105 cells per well in a 12-well dish. After
overnight culture, the cells were pretreated for 1 hour with
vehicle, WAY-169916 (1 µM), or PDTC (100 µM), fol-
lowed by stimulation for 1 hour with TNF-α (100 U/ml).
Synoviocyte RNA was isolated after the 1 hour of TNF-α
treatment, and gene expression analysis was performed
using real-time RT–PCR with an ABI PRISM 7900
Sequence Detection System, in accordance with the man-
ufacturer's protocol (Applied Biosystems). The data were
analyzed with Sequence Detector v2.1 software (Applied
Biosytems) and normalized to glyceraldehyde-3-phosphate
dehydrogenase with the Applied Biosystems primer set.
Values are reported as means ± SEM for each group from
two experiments, with n = 3. The data were analyzed by
one-way ANOVA and differences were deemed significant
if P < 0.05.
Results
Activity in the hla-b27 transgenic rat
The HLA-B27 transgenic rat expresses two human proteins
(HLA-B27 and β2-microglobulin) that, over time, provoke a
misdirected immune response. This model represents a
chronic intestinal inflammation with associated arthritis
induced by the human class I major histocompatibility allele
HLA-B27, which is strongly associated with human dis-
ease. Treatment of male HLA-B27 transgenic rats with con-
centrations of WAY-169916 as low as 0.05 mg/kg rapidly
converts the chronic diarrhea that these rats experience to
a normal stool [27]. If the disease is allowed to progress,
they begin to show symptoms of arthritis. In these settings,
treatment of WAY-169916 at a single oral dosage of 10
mg/kg per day restored the clinical joint scores to baseline
after 10 days, while a sub-optimal dose of prednisolone
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scores (Fig. 1). Histological scoring of synovitis and carti-
lage damage in the tarsal joints after 29 days of treatment
was also conducted. Treatment with WAY-169916 signifi-
cantly decreased the synovitis parameters of synovial struc-
ture, fibroplasia, inflammatory cell infiltrates, and total
synovitis score, and also significantly improved all cartilage
parameters monitored (Table 1).
Activity of WAY-169916 in the Lewis rat adjuvant-
induced arthritis model
WAY-169916 was then given a more thorough evaluation
in the male Lewis rat adjuvant-induced arthritis model. The
disease in this model is a migratory polyarthritis affecting
primarily the tarsal, metatarsal, and interphalangeal joints.
The hallmarks of the model include polyarticular inflamma-
tion, marked bone resorption, and periosteal bone prolifer-
ation. When immunized with CFA, the joints of Lewis rats
swell markedly over a period of 8 days. After maximal swell-
ing had occurred, rats received an oral daily dose of WAY-
169916, making this a therapeutic dosing regimen. Joint
swelling was rapidly and markedly reduced in rats treated
with WAY-169916. Full efficacy was seen with oral doses
of 0.3 mg/kg or higher (Fig. 2) but efficacy was decreased
at a dose of 0.1 mg/kg. However, both doses were effec-
tive at reversing tarsal joint destruction as assessed by
synovitis and cartilage (Mankin) scores (Table 2). Incre-
mental improvements in the histology scores were
observed with higher doses of WAY-169916 (data not
shown), suggesting that continued improvements in joint
lesions might occur with a longer duration of treatment or
with higher dosages.
Because both the HLA-B27 transgenic rat and Lewis rat
studies used males, the efficacy of WAY-169916 (5 mg/
kg) was compared in intact male and female Lewis rats with
the same experimental design as described above. The
joint (Fig. 2b) and histology scores (not shown) for the two
Table 1
Histological scoring of synovitis and cartilage damage in the tarsal joints from HLA-B27 transgenic rats
Group Synovial structure (0–3) Fibroplasia (0–3) Inflammatory cells (0–3) Pannus (0–2) Total synovitis score (0–11)
T/MC vehicle 3.00 ± 0.00 2.80 ± 0.45 3.00 ± 0.00 1.60 ± 0.89 10.40 ± 1.34
WAY-169916, 10 mg/kg 1.80 ± 0.45* 1.20 ± 0.84* 1.40 ± 0.55*† 0.40 ± 0.89 5.00 ± 2.24*†
Prednisolone, 0.6 mg/kg 2.40 ± 0.55 2.00 ± 0.71* 2.00 ± 0.00* 1.60 ± 0.89 8.00 ± 1.87





T/MC vehicle 3.80 ± 0.84 2.80 ± 0.45 3.20 ± 0.45 0 9.80 ± 1.48
WAY-169916, 10 mg/kg 2.20 ± 0.45*† 2.00 ± 0.45*† 1.60 ± 0.55*† 0 5.80 ± 0.84*†
Prednisolone, 0.6 mg/kg 3.40 ± 0.55 2.20 ± 0.45* 3.00 ± 0.00 0 8.60 ± 0.89
Results are means ± SD.
*Significantly less than vehicle (P < 0.005). †Significantly less than prednisolone (P < 0.005).
Table 2
Histological scoring of synovitis and cartilage changes in the tarsal joints from rats with adjuvant-induced arthritis
Group Synovial structure (0–3) Fibroplasia (0–3) Inflammatory cells (0–3) Pannus (0–2) Total synovitis score (0–11)
T/MC vehicle 2.92 ± 0.21 2.67 ± 0.41 2.92 ± 0.21 2.00 ± 0.00 10.5 ± 0.63
WAY-169916, 0.3 mg/kg 2.33 ± 0.41* 2.33 ± 0.52 1.58 ± 0.38* 1.17 ± 0.75 7.42 ± 1.88*
WAY-169916, 0.1 mg/kg 2.17 ± 0.68* 1.92 ± 0.49* 1.50 ± 0.45* 0.83 ± 0.98* 6.42 ± 2.90*
Group Cartilage structure (0–6) Cartilage cells (0–3) Safranin-O/Fast Green staining (0–4) Tidemark integrity (0–1) Total Mankin score (0–14)
T/MC vehicle 3.52 ± 0.42 2.33 ± 0.41 3.00 ± 0.00 0 8.58 ± 0.74
WAY-169916, 0.3 mg/kg 1.75 ± 0.69* 1.58 ± 0.38* 1.83 ± 0.41* 0 5.17 ± 1.77*
WAY-169916, 0.1 mg/kg 2.25 ± 0.42* 1.42 ± 0.49* 1.67 ± 0.41* 0 5.33 ± 1.21*
Results are means ± SD.
*Significantly less than vehicle (P < 0.005).
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utility of WAY-169916 is restricted by gender.
Mechanism of action of WAY-169916
Because WAY-169916 has been shown to antagonize NF-
κB transcriptional activity selectively [27], we wished to
begin to address how WAY-169916 might be functioning
to improve disease symptoms in the rat adjuvant model.
Previous studies have shown changes in concentrations of
rat serum proteins induced by adjuvant administration
(reviewed in [30]). We decided to look at three acute-
phase proteins, haptoglobin, α1-AGP, and CRP, that are
induced by the adjuvant and have been correlated with RA
progression in humans [31]. Serum was analyzed from
male Lewis rats treated with 5 mg/kg WAY-169916 for 10
days. As shown in Fig. 3, both haptoglobin and α1-AGP
serum levels were induced about 300 to 400% by adjuvant
treatment, whereas CRP inductions were more modest
(40%); this was consistent with previous reports [30].
WAY-169916 inhibited the adjuvant induction of all three
acute-phase proteins but had no effect on their basal levels.
We also performed gene expression profile analysis from
the spleen, liver, and popliteal lymph nodes from these rats.
In the spleen, 36 genes were identified that were induced
twofold by adjuvant treatment (average fold change; Table
3). Of those 36 genes, WAY-169916 decreased the
expression of 29 of them by at least 50%. Several genes
that have been implicated in the pathogenesis of RA that
were regulated by WAY-169916 include LBS binding pro-
tein (LBP), CD14, MMP-9, IL1R2, S100A8, and S100A9.
As a control, the regulation of LBP, haptoglobin, and
S100A9 was confirmed by real-time RT–PCR (Fig. 4a). A
similar global inhibition of adjuvant-induced genes by
WAY-169916 was also observed in liver and popliteal
lymph node gene-profiling studies. In the liver, 47 genes
were induced and WAY-169916 inhibited 43 of those by
50%; in the lymph node, 143 genes were induced and 61
of those were repressed by 50% by WAY-169916 (data
not shown).
In addition, we attempted to determine whether treatment
with WAY-169916 resulted in direct interference of NF-κB
DNA binding in primary spleen cell cultures. The cells were
stimulated with ConA (5 µg/ml) for 24 hours and co-treated
with either WAY-169916 (1 µM) or PDTC (100 µM), a
general inhibitor of NF-κB. As shown in Fig. 4b, activation
by ConA resulted in an 80% increase in NF-κB DNA bind-
ing. Although PDTC treatment could completely block NF-
κB activation, WAY-169916 was without effect. Control
experiments demonstrated that the binding of NF-κB was
specific, because competition experiments with wild-type
oligonucleotide interfered with binding activity whereas a
mutated oligonucleotide was without effect (data not
shown). These results are consistent with our previous
observations [16,27] demonstrating that liganded ER
inhibits NF-κB at the transcriptional level downstream from
NF-κB DNA binding. Overall, these data indicate a marked
anti-inflammatory effect for WAY-169916 that seems to
cross multiple signaling pathways and tissues consistent
with NF-κB's ubiquitous role in inflammation.
WAY-169916 anti-inflammatory activity in synoviocytes 
isolated from patients with RA
Finally, we wished to test whether WAY-169916 is active
in FLS, a human cell type that is thought to have a patho-
logic function in joint destruction through its production of
inflammatory cytokines and MMPs [32]. Activation of NF-
κB in FLS is necessary for the production of these inflam-
matory mediators [5,6]. FLS obtained from male patients
with RA were stimulated with TNF-α and treated with vehi-
cle, WAY-169916 (1 µM), or PDTC (100 µM). RNA was
analyzed for gene expression changes of intercellular cell-
adhesion molecule-1 (ICAM-1), IL-6, and TNF-α by real-
time RT–PCR. As shown in Fig. 5, TNF-α-stimulated
expression of all three inflammatory genes was significantly
blocked by both WAY-169916 and PDTC, which was con-
sistent with previous observations [5]. The cells were con-
firmed to express ERα mRNA [33] but no ERβ mRNA was
Figure 1
WAY-169916 improves joint scores in HLA-B27 transgenic rat model of arthritis
of arthritis. HLA-B27 transgenic rats, 26 to 28 weeks old, presenting 
signs of arthritis were treated orally daily with vehicle, prednisolone (0.6 
mg/kg), or WAY-169916 (10 mg/kg) for 29 days. Joint scores were 
assessed by evaluating hindpaws for erythema and swelling (0 to 3 
each; maximal score of 12).
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potential utility of non-steroidal selective NF-κB modulators
such as WAY-169916 in treating patients with RA.
Discussion
RA might occur as a result of an autoimmune response, and
recent studies suggest that hypersensitivity to microbial
antigens contributes to the development of the arthritis.
Microbial or self-antigen presentation to T lymphocytes
Figure 2
WAY-169916 improves joint scores in a dose-dependent fashion in rat adjuvant-induced arthritis modeli   - t fashion in rat adjuvant-induced arthritis model. (a) Male Lewis rats were injected with com-
plete Freund's adjuvant on day 1 and maximal inflammation was allowed to develop. Beginning on day 8 and continuing until day 22, rats were 
treated daily with oral vehicle or WAY-169916 (0.3 and 0.1 mg/kg). Joint scores were assessed by evaluating hindpaws for erythema and swelling 
(0 to 3 each; maximal score of 12). (b) WAY-169916 improves joint scores in rat adjuvant-induced arthritis model in both males and females. Exper-
iments were performed as in (a) except that WAY-169916 was dosed daily at 5 mg/kg orally in both intact male and intact female rats.
Figure 3
WAY-169916 inhibits the adjuvant-induced expression of serum acute-phase proteini i  f r  a t - as  protein. Serum from control male rats or adjuvant-induced rats treated 
with either vehicle or WAY-169916 (5 mg/kg) was analyzed for the expression of (a) haptoglobin, (b) α1-acid glycoprotein (α1-AGP) or (c) C-reac-
tive protein (CRP) by radial immunodiffusion assay. Results are expressed as means ± SEM from six rats per group. *P < 0.05 compared with vehi-
cle control. CFA, complete Freund's adjuvant.
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proinflammatory mediators, including IL-1, TNF-α, inter-
feron-γ, and MMPs mediate the inflammation of the joints.
Biochemical and histological changes in synovial tissue,
cartilage, and bone have been documented in various
animal models of arthritis [34,35]. In many respects the
synovial and cartilage lesions that develop in these models
closely resemble those seen in rheumatoid arthritis. We
have investigated the role of WAY-169916 in two such
models.
The HLA-B27 transgenic rats spontaneously develop
arthritis similar to the human spondyloarthropathies associ-
ated with the HLA-B27 and β2-microglobulin genes
through a T cell-mediated process [34]. In this model,
WAY-169916 restored the clinical joint scores to baseline
after 10 days. Histological scoring of synovitis and cartilage
damage in the tarsal joints after 29 days of treatment was
also significantly improved with WAY-169916 treatment.
In the rat adjuvant-induced arthritis model [36], 3 to 6 days
after the injection of adjuvant, induction of an αβ T cell
response occurs and leads to clinical lesion development
in the tarsal joints within 5 to 8 days. Because activated NF-
κB was detected in the synovial lining layer and around
blood vessels in the inflamed synovium as early as day 3
after adjuvant injection in the Lewis rats and is thought to
be correlated with disease development [37], this model
was used to test the therapeutic treatment with WAY-
169916. We demonstrated that WAY-169916 was effec-
tive in improving both joint and histology scores at doses as
low as 0.3 mg/kg given orally once daily. Improvement in
the synovitis and Mankin scores did occur with higher
doses of WAY-169916 even though the joint score reduc-
tion was already maximal at 0.3 mg/kg. When the rats were
dosed at 5 mg/kg the total synovitis score decreased to
4.14 (data not shown). The beneficial effects of WAY-
169916 on joint histology might therefore continue with
increasing dose or longer exposure.
A benefit on arthritis progression with non-selective estro-
gens such a 17β-estradiol has also been demonstrated in
both the rat adjuvant-induced arthritis model [38] and the
collagen-induced mouse model [39,40]. Indeed, 17β-
estradiol has been shown to affect several processes
involved in the pathogenesis of RA, including immunoregu-
lation, regulation of adhesion molecules, and modulation of
cytokine signaling. However, the role of estrogen has not
Figure 4
The effect of WAY-169916 in spleen cells. (a) The regulation of LBS binding protein (LBP), haptoglobin and S100A9 gene expression by WAY-
169916 from spleens from the rat adjuvant model were confirmed by real-time RT–PCR (grey bars) compared with the regulation observed in the 
gene-profiling experiments (black bars). Results are expressed as means ± SEM from six rats per group. *P < 0.05 compared with vehicle control. 
(b) Treatment with WAY-169916 does not interfere with the binding of NF-κB to DNA. Nuclear extracts from primary mouse spleen cell cultures 
were co-treated for 18 hours with vehicle or concanavalin A (ConA; 5 µg/ml) and either WAY-169916 (1 µM) or pyrrolidine dithiocarbamate (PDTC) 
(100 µM) as indicated. CFA, complete Freund's adjuvant.
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WAY-169916 gene-profiling experiment with spleen from rat adjuvant arthritis model
Av. control Av. CFA Av. CFA + WAY-
169916
AFC CFA AFC WAY-169916 Inhibition by WAY-169916 
(%)
Transcription factors
CCAAT/enhancer binding protein (C/EBP), 
beta
16.8 39.8 19.6 2.37 0.49 87.6
NF-E2-related factor 2 14.2 30.3 19.6 2.13 0.65 66.2
Immune mediators
Mast cell protease 2 5.3 11.8 5.9 2.20 0.50 91.4
Arachidonate 5-lipoxygenase-activating 
protein
18.9 46.5 23.9 2.46 0.51 82.0
Chemokine-like factor 1 10.5 28.9 18.9 2.75 0.65 54.3
Phospholipase A2, group IIA 33.8 71.7 60.3 2.12 0.84 30.0
Proteoglycan 2, bone marrow 27.6 147.4 59.1 5.34 0.40 73.7
Immune related
CD14 antigen 15.9 32.3 19.1 2.04 0.59 80.2
Peptidoglycan recognition protein 10.2 39.6 14.5 3.88 0.37 85.2
Lipopolysaccharide-binding protein 3.3 10.2 4.4 3.10 0.43 83.6
IL-1 receptor, type II 2.2 8.1 3.5 3.71 0.44 76.8
Defensin RatNP-3 precursor 31.7 105.3 63.5 3.32 0.60 56.8
Suppressor of cytokine signalling 3 15.2 35.3 15.2 2.33 0.43 99.7
Complement component 3 13.3 28.4 24.2 2.14 0.85 27.6
Defensin NP-2 precursor 58.9 166.6 102.8 2.83 0.62 59.3
Defensin NP-4 precursor 54.1 164.9 104.7 3.05 0.64 54.3
Paired immunoglobulin-like receptor-B 11.0 22.7 18.3 2.07 0.81 37.6
25 oligoadenylate synthetase 24.6 51.4 24.8 2.09 0.48 99.2
Tumor necrosis factor receptor II 7.3 15.8 8.9 2.18 0.56 81.0
S100 calcium-binding protein A8 (calgranulin 
A)
52.2 184.5 91.5 3.54 0.50 70.3
S100 calcium-binding protein A9 (calgranulin 
B)
144.9 382.7 242.1 2.64 0.63 59.1
Ficolin B 42.3 121.1 74.7 2.86 0.62 58.9
Myelin and lymphocyte protein 11.8 27.6 19.9 2.34 0.72 49.1
Protease
Matrix metalloproteinase 9 2.0 8.4 3.5 4.24 0.42 75.8
Chymase 1 2.9 9.2 5.1 3.16 0.56 64.8
Transport
Monocarboxylate transporter 10.3 24.4 10.0 2.38 0.41 102.3
Lipocalin 2 16.3 55.3 33.0 3.39 0.60 57.1
Acute phase
Haptoglobin 10.5 37.5 12.9 3.58 0.34 90.9
Metabolism
Uridine phosphorylase I 8.9 32.8 9.1 3.68 0.28 99.3
Guanine deaminase 17.8 39.5 20.7 2.21 0.52 86.9
Available online http://arthritis-research.com/content/7/3/R427
R435been well defined in patients with RA. There is evidence
that gender might affect the occurrence and progression of
RA. Women have a higher risk of developing RA than men.
During pregnancy, the disease activity is ameliorated in
75% of women, whereas after delivery, flares occur in up to
90% of patients [41]. The highest incidence of developing
RA coincides with menopause, indicating that a decrease
in estrogen production might increase the risk of joint
inflammation. In a recent randomized clinical trial, post-
menopausal women taking hormone therapy had sup-
pressed signs of inflammation and significantly improved
disease severity scores (DS28) after 12 months of treat-
ment, which was consistent with previous trials [42].
With the identification of selective NF-κB transcriptional
inhibitors such as WAY-169916, the expectation is to
accentuate the anti-inflammatory, anti-rheumatic activity
observed with the non-selective estrogens. Whereas non-
selective estrogens have been documented to contain an
anti-inflammatory activity through the suppression of NF-κB
transcriptional activity [11,12], hormone therapy can simul-
taneously elicit both proinflammatory and anti-inflammatory
activities as exemplified by the decrease in haptoglobin and
α1-AGP levels in women taking hormone therapy [43]
while also inducing MMP9 and CRP levels [44,45]. In the
rat adjuvant model, WAY-169916 inhibited the adjuvant
induction of CRP levels and those of haptoglobin and α1-
AGP. Moreover, WAY-169916 had no effect on the basal
levels of CRP whereas treatment with estradiol has been
shown to increase rat CRP serum levels [46], suggesting a
potential differential effect of WAY-169916 in comparison
with estradiol. This differential activity has been demon-
strated on several classic estrogenic effects. WAY-
169916 neither stimulates creatine kinase gene expression
driven via an estrogen receptor response element in vitro
nor promotes uterine proliferation in vivo [27] while retain-
ing the anti-inflammatory activity as demonstrated here.
The anti-inflammatory activity of WAY-169916 was further
demonstrated in a series of gene-profiling experiments. In
the spleens from the adjuvant-treated rats, 36 genes were
identified that were induced greater than twofold by the
adjuvant treatment. WAY-169916, when dosed at 5 mg/
kg, repressed 29 of those genes by at least 50%, and 17
of them by more than 75%. An attractive hypothesis for
WAY-169916-mediated activity in the spleen involves the
downregulation of LBP and CD14 expression on mono-
cytes and macrophages, resulting in a diminished immune
response and ultimately resulting in the observed
decreases in MMP9, IL1R2, chemokine-like factor 1,
S100A8, and S100A9 through the repression of NF-κB
activity [47,48]. In spleen cell cultures, WAY-169916 treat-
ment did not interfere with ConA-stimulated NF-κB DNA
binding; however, the downregulation of S100A9 mRNA
was confirmed (data not shown), which was consistent
with our hypothesis that ER regulates NF-κB at the tran-
scriptional level [16,27]. A similar suppression of adjuvant-
induced inflammatory gene expression was also observed
in liver and lymph node studies. These data demonstrate
that WAY-169916 can have an effect on a global level,
both in terms of the tissues targeted and the different
inflammatory signaling pathways, to suppress adjuvant-
induced gene expression.
Infiltration of inflammatory cells into the synovial tissue and
lining layer results in the formation of pannus, a highly vas-
cularized tissue comprising FLS, macrophages, and lym-
phocytes. FLS are known for their role in joint destruction
through the production of cytokines and MMP, which con-
tribute to cartilage degradation (reviewed in [49]). Expres-
sion of ER has been detected in synovial tissues from
patients with RA [50] and localized to synoviocytes in the
synovial lining [22], providing another potential cell type by
which WAY-169916 functions. Synoviocytes isolated from
a male RA patient were confirmed to express ERα mRNA
[33], but no ERβ mRNA was detected (data not shown).
The ERα was functional in these cells, because WAY-
169916 could effectively block the TNF-α-mediated inflam-
matory gene expression of IL-6, TNF-α, and ICAM-1. The
potential involvement of NF-κB in mediating TNF-α gene
induction was demonstrated with the use of a general NF-
κB inhibitor, as shown previously [5]. Given the importance
Microsomal glutathione S-transferase 1 40.0 87.6 51.2 2.19 0.58 76.6
GTP cyclohydrolase 1 11.6 25.5 23.6 2.20 0.93 13.8
Hepatic steroid hydroxylase II A2 9.0 18.7 21.5 2.07 1.15 -29.0
Adhesion
C-CAM4 protein 11.5 24.5 16.0 2.12 0.65 65.6
Fibronectin 1 57.2 116.6 91.3 2.04 0.78 42.6
Unknown function
Expressed sequence tag 20.0 41.5 25.1 2.08 0.61 76.1
AFC, average fold change; Av., average; CFA, complete Freund's adjuvant.
Table 3 (Continued)
WAY-169916 gene-profiling experiment with spleen from rat adjuvant arthritis model
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R436of TNF-α signaling in RA disease progression, the ability of
WAY-169916 to interfere with this signaling pathway in
human synoviocytes suggests a potential clinical benefit for
WAY-169916 in patients with RA.
Conclusions
We detailed the activity of the first pathway-selective ER
ligand, WAY-169916, in two models of RA. This com-
pound selectively inhibits NF-κB activity via the ER and
imparts significant efficacy in the HLA-B27 and Lewis rat
adjuvant-induced models of arthritis. More importantly, no
evidence for classic estrogenic activity has been observed
with this compound [27]. These data provide evidence that
the non-steroidal, pathway-selective ER ligand, WAY-
169916, and other compounds in its class might be thera-
peutically useful in the treatment of RA.
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